Literature DB >> 24355800

Multiparametric cardiovascular magnetic resonance assessment of cardiac allograft vasculopathy.

Christopher A Miller1, Jaydeep Sarma2, Josephine H Naish3, Nizar Yonan2, Simon G Williams2, Steven M Shaw2, David Clark4, Keith Pearce5, Martin Stout5, Rahul Potluri6, Alex Borg5, Glyn Coutts7, Saqib Chowdhary2, Gerry P McCann8, Geoffrey J M Parker3, Simon G Ray2, Matthias Schmitt2.   

Abstract

OBJECTIVES: This study sought to evaluate the diagnostic performance of multiparametric cardiovascular magnetic resonance (CMR) for detecting cardiac allograft vasculopathy (CAV) using contemporary invasive epicardial artery and microvascular assessment techniques as reference standards, and to compare the performance of CMR with that of angiography.
BACKGROUND: CAV continues to limit the long-term survival of heart transplant recipients. Coronary angiography has a Class I recommendation for CAV surveillance and annual or biannual surveillance angiography is performed routinely in most centers.
METHODS: All transplant recipients referred for surveillance angiography at a single UK center over a 2-year period were prospectively screened for study eligibility. Patients prospectively underwent coronary angiography followed by coronary intravascular ultrasound, fractional flow reserve, and index of microcirculatory resistance. Within 1 month, patients underwent multiparametric CMR, including assessment of regional and global ventricular function, absolute myocardial blood flow quantification, and myocardial tissue characterization. In addition, 10 healthy volunteers underwent CMR.
RESULTS: Forty-eight patients were recruited, median 7.1 years (interquartile range: 4.6 to 10.3 years) since transplantation. The CMR myocardial perfusion reserve was the only independent predictor of both epicardial (β = -0.57, p < 0.001) and microvascular disease (β = -0.60, p < 0.001) on stepwise multivariable regression. The CMR myocardial perfusion reserve significantly outperformed angiography for detecting moderate CAV (area under the curve, 0.89 [95% confidence interval (CI): 0.79 to 1.00] vs. 0.59 [95% CI: 0.42 to 0.77], p = 0.01) and severe CAV (area under the curve, 0.88 [95% CI: 0.78 to 0.98] vs. 0.67 [95% CI: 0.52 to 0.82], p = 0.05).
CONCLUSIONS: CAV, including epicardial and microvascular components, can be detected more accurately using noninvasive CMR-based absolute myocardial blood flow assessment than with invasive coronary angiography, the current clinical surveillance technique.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac allograft vasculopathy; cardiovascular magnetic resonance; diagnosis; microvascular disease; myocardial blood flow

Mesh:

Year:  2013        PMID: 24355800     DOI: 10.1016/j.jacc.2013.07.119

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  18 in total

Review 1.  Transplant allograft vasculopathy: Role of multimodality imaging in surveillance and diagnosis.

Authors:  Gregory A Payne; Fadi G Hage; Deepak Acharya
Journal:  J Nucl Cardiol       Date:  2015-12-28       Impact factor: 5.952

2.  Myocardial tissue remodeling after orthotopic heart transplantation: a pilot cardiac magnetic resonance study.

Authors:  Otavio Rizzi Coelho-Filho; Ravi Shah; Carlos Fernando Ramos Lavagnoli; Jose Carlos Barros; Tomas G Neilan; Venkatesh L Murthy; Pedro Paulo Martins de Oliveira; Jose Roberto Matos Souza; Elaine Soraya Barbosa de Oliveira Severino; Karlos Alexandre de Souza Vilarinho; Lindemberg da Mota Silveira Filho; Jose Garcia; Marc J Semigran; Otavio Rizzi Coelho; Michael Jerosch-Herold; Orlando Petrucci
Journal:  Int J Cardiovasc Imaging       Date:  2016-07-20       Impact factor: 2.357

Review 3.  Imaging in patients after cardiac transplantation and in patients with ventricular assist devices.

Authors:  Bhanu Gupta; Dany Jacob; Randall Thompson
Journal:  J Nucl Cardiol       Date:  2015-04-02       Impact factor: 5.952

4.  Semi-quantitative myocardial perfusion MRI in heart transplant recipients at rest: repeatability in healthy controls and assessment of cardiac allograft vasculopathy.

Authors:  Travis B DeSa; Muhannad A Abbasi; Julie A Blaisdell; Kai Lin; Jeremy D Collins; James C Carr; Michael Markl
Journal:  Clin Imaging       Date:  2019-12-19       Impact factor: 1.605

5.  Imaging in patients with advanced therapies for heart failure.

Authors:  Joanna M Joly; Steven G Lloyd
Journal:  J Nucl Cardiol       Date:  2015-03-31       Impact factor: 5.952

6.  CMR-derived extracellular volume fraction (ECV) in asymptomatic heart transplant recipients: correlations with clinical features and myocardial edema.

Authors:  Yating Yuan; Jie Cai; Yue Cui; Jing Wang; Osamah Alwalid; Xuehua Shen; Yukun Cao; Yan Zou; Bo Liang
Journal:  Int J Cardiovasc Imaging       Date:  2018-07-28       Impact factor: 2.357

7.  New developments for the detection and treatment of cardiac vasculopathy.

Authors:  Kevin J Clerkin; Ziad A Ali; Donna M Mancini
Journal:  Curr Opin Cardiol       Date:  2017-02-15       Impact factor: 2.161

Review 8.  Diagnosis and management of coronary allograft vasculopathy in children and adolescents.

Authors:  Nathalie Dedieu; Gerald Greil; James Wong; Matthew Fenton; Michael Burch; Tarique Hussain
Journal:  World J Transplant       Date:  2014-12-24

9.  Myocardial perfusion reserve and global longitudinal strain as potential markers of coronary allograft vasculopathy in late-stage orthotopic heart transplantation.

Authors:  Akhil Narang; John E Blair; Mita B Patel; Victor Mor-Avi; Savitri E Fedson; Nir Uriel; Roberto M Lang; Amit R Patel
Journal:  Int J Cardiovasc Imaging       Date:  2018-05-04       Impact factor: 2.357

10.  Cardiac Structure-Function MRI in Patients After Heart Transplantation.

Authors:  Ryan S Dolan; Amir A Rahsepar; Julie Blaisdell; Kai Lin; Kenichiro Suwa; Kambiz Ghafourian; Jane E Wilcox; Sadiya S Khan; Esther E Vorovich; Jonathan D Rich; Allen S Anderson; Clyde W Yancy; Jeremy D Collins; Michael Markl; James C Carr
Journal:  J Magn Reson Imaging       Date:  2018-08-24       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.